Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials

Download
Author
Rasmussen, TA; Tolstrup, M; Winckelmann, A; Ostergaard, L; Sogaard, OSDate
2013-04-01Source Title
Human Vaccines and ImmunotherapeuticsPublisher
TAYLOR & FRANCIS INCUniversity of Melbourne Author/s
Rasmussen, ThomasAffiliation
Doherty InstituteMetadata
Show full item recordDocument Type
Journal ArticleCitations
Rasmussen, T. A., Tolstrup, M., Winckelmann, A., Ostergaard, L. & Sogaard, O. S. (2013). Eliminating the latent HIV reservoir by reactivation strategies Advancing to clinical trials. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 9 (4), pp.790-799. https://doi.org/10.4161/hv.23202.Access Status
Open AccessDOI
10.4161/hv.23202Abstract
Combination antiretroviral therapy (cART) has transformed HIV from a deadly to a chronic disease, but HIV patients are still burdened with excess morbidity and mortality, long-term toxicities from cART, stigmatization, and insufficient access to cART worldwide. Thus, a cure for HIV would have enormous impact on society as well as the individual. As the complexity and mechanisms of HIV persistence during therapy are being unraveled, new therapeutic targets for HIV eradication are discovered. Substances that activate HIV production in the latently infected cells have recently received much attention. By turning on expression of latent HIV proviruses, reactivation strategies could contribute to the eradication HIV infection. Compounds that are currently being or soon to be tested in clinical trials are emphasized. The results from these trials will provide important clues as to whether or not reactivating strategies could become significant components of a cure for HIV.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References